Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
+9.86%
-6.83%
+1.36%
-1.12%
-1.93%
NVS
Novartis AG
$115.77
Chart
$110.13 (+5.12%)
$110.14 (+5.11%)
$110.14 (+5.11%)
$108.13 (+7.07%)
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+9.86%
-6.83%
+1.36%
-1.12%
-1.93%
NVS
Novartis AG
Current Price
$115.77
Login to view Novartis AG (NVS) recommendation from the last 90 days from financial news and social media.
Chart
$110.13 (+5.12%)
$110.14 (+5.11%)
$110.14 (+5.11%)
$108.13 (+7.07%)
NVS Latest Analysis
Novartis AG (NVS) Hit a 52 Week High Can the Run Continue?. Novartis (NVS) is at a 52-week high but can investors hope for more gains in the future? We take a look at the companys fundamentals for clues.
Fri Jun 13, 2025
Tonix Pharmaceuticals Announces Appointment of Commercial Industry Veteran James Jim Hunter to Board of Directors. Mr. Hunter brings more than 40 years of experience building and leading commercial organizations in the biopharmaceutical industry including leadership roles at Validus Pharmaceuticals Relialab and Novartis
Fri Jun 13, 2025
Nanotechnology in Cancer Treatment Market Positioned for Transformational Growth by 2029. Boston June 05 2025 (GLOBE NEWSWIRE) -- As cancer prevalence continues to rise globally nanotechnology in cancer treatment is emerging as a transformative force in oncology. Leveraging nanoscale drug delivery systems and precision-targeting techniques companies such as AstraZeneca F. Hoffmann-La Roche Ltd. and Bristol-Myers Squibb are developing next-generation solutions to enhance therapeutic effectiveness
Thu Jun 5, 2025
Global Antidote Market to Cross the USD 4 Billion Mark by 2032 | DelveInsight. Global Antidote Market to Cross the USD 4 Billion Mark by 2032 |. DelveInsightThe antidote market is witnessing substantial growth largely propelled by the growing incidence of poisoning drug overdoses and snake or animal bites. This rising demand is supported by greater public health awareness government efforts to combat drug overdoses and continuous progress in product innovation. Moreover strategic product lau
Thu Jun 5, 2025
Is Novartis Gaining or Losing Market Support?. ) short percent of float has fallen 26.09% since its last report. The company recently reported that it has Short interest is the number of shares that have been sold short but have not yet been covered or closed out. is when a trader sells shares of a company they do not own with the hope that the price will fall. Traders make money from short selling if the price ...
Wed Jun 4, 2025
Huntingtons Disease Clinical Trial Pipeline Analysis: 20 Key Companies Shaping the Future of Dopamine Receptor Antagonists Therapeutics | DelveInsight. Huntington'.s Disease Clinical Trial Pipeline Analysis: 20 Key Companies Shaping the Future of Dopamine Receptor Antagonists Therapeutics |. DelveInsightThe Huntington'.s disease treatment market is poised for significant growth driven by rising prevalence rates and increased awareness globally. Advancements in gene-targeting and disea
Tue Jun 3, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Hover over the category for more information
